Abstract
Background
Oral physiotherapy or mouth exercise is considered to be an adjunct but mandatory treatment modality for oral submucous fibrosis (OSMF). This study planned to evaluate the clinical efficacy of a newly designed mouth exercising device (MED) in OSMF patients receiving local ointment, intra-lesional drugs and surgical treatment.Materials and methods
A total of 231 OSMF patients were selected and treated with basic regime including topical corticosteroids, oral antioxidants and the icecream-stick exercise regime and allotted randomly to two equal groups A and B. Group-A patients were additionally given MED. Subgroups A1 and B1 patients with an inter-incisal distance (IID) 20-35mm were not given any additional therapy; subgroup A2 and B2 patients (IID 20-35mm) were treated additionally with intra-lesional injections. Subgroups A3 and B3 with IID<20mm were managed surgically. IID was measured at baseline and at 6 months recall. The change in IID measurements was calculated and statistically analyzed using 2-way ANOVA and Tukeys multiple post hoc analysis.Results
Average improvement in IID after six months of recall visits was observed to be 8.4 mm in subgroup-A1 (n-53) compared to 5.5 mm in B1(n-50) (p<0.01). The IID improvement in subgroup-A2 was found to be 9.3mm (n-46) compared to 5.1 mm in B2 (n-48) (p<0.01). In the surgery group, mouth opening improvement was observed to be 9.6 mm in subgroup A3 (n-18) compared to 4.8 mm for B3 (n-16) (p<0.01).Conclusions
Use of the MED appears to be effective for increasing oral opening in OMSF patients in conjunction with local, injection and/or surgical treatment.Full text links
Read article at publisher's site: https://doi.org/10.7314/apjcp.2016.17.3.1255
Read article for free, from open access legal sources, via Unpaywall: http://koreascience.or.kr:80/article/JAKO201613752759129.pdf
Citations & impact
Impact metrics
Citations of article over time
Article citations
MIAT promotes myofibroblastic activities and transformation in oral submucous fibrosis through sponging the miR-342-3p/SOX6 axis.
Aging (Albany NY), 16(19):12909-12927, 07 Oct 2024
Cited by: 0 articles | PMID: 39379100 | PMCID: PMC11501384
Interventions for managing oral submucous fibrosis.
Cochrane Database Syst Rev, 2:CD007156, 28 Feb 2024
Cited by: 2 articles | PMID: 38415846
Review
Evaluating the Oral-Health-Related Quality of Life of Oral Submucous Fibrosis Patients before and after Treatment Using the OHIP-14 Tool.
Int J Environ Res Public Health, 19(3):1821, 05 Feb 2022
Cited by: 5 articles | PMID: 35162842 | PMCID: PMC8835519
A New Intraoral Appliance for Trismus in Oral Submucous Fibrosis.
Case Rep Dent, 2018:1039391, 09 Sep 2018
Cited by: 1 article | PMID: 30271636 | PMCID: PMC6151238
Current protocols in the management of oral submucous fibrosis: An update.
J Oral Pathol Med, 46(6):418-423, 04 May 2017
Cited by: 10 articles | PMID: 28391602
Review
Go to all (6) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
A randomized control trial measuring the effectiveness of a mouth-exercising device for mucosal burning in oral submucous fibrosis.
Oral Surg Oral Med Oral Pathol Oral Radiol, 122(6):713-718, 06 Aug 2016
Cited by: 6 articles | PMID: 27720659
Novel mouth-exercising device for oral submucous fibrosis.
J Prosthodont, 21(7):556-560, 10 Jul 2012
Cited by: 7 articles | PMID: 22779909
A comparative study to evaluate the efficacy of lycopene and curcumin in oral submucous fibrosis patients: A randomized clinical trial.
Indian J Dent Res, 29(3):303-312, 01 May 2018
Cited by: 23 articles | PMID: 29900913
Antioxidant treatments in patients with oral submucous fibrosis: A systematic review.
J Oral Pathol Med, 53(1):31-41, 28 Dec 2023
Cited by: 1 article | PMID: 38155549
Review